2022 CSCO |Professor Jiang Zefei: CSCO Academic Week kicked off in Beijing, focusing on cutting-edge progress and sharing academic feasts

Edited and written by Yimaitong, please do not reprint
without authorization.

The 25th National Congress of Clinical Oncology and the 2022 CSCO Annual Conference were held
in Beijing on November 5.
The conference focuses on the clinical frontier of oncology, invites well-known experts and scholars at home and abroad to make wonderful progress reports or lectures, and strives to comprehensively and accurately reflect new concepts and new trends
in the field of clinical oncology.
On the occasion of this conference, Yimaitong specially invited Professor Jiang Zefei, Vice President and Secretary-General of the Chinese Society of Clinical Oncology (CSCO), to share the highlights of the CSCO Annual Conference, the standardized diagnosis and treatment of breast cancer, and the application of
artificial intelligence in the field of oncology.

Yimaitong: The academic week of this year's CSCO Annual Conference was held in the mode of "online + offline", which not only brought together the progress of multi-tumor diagnosis and treatment, but also focused on innovative tumor drugs, artificial intelligence, patient education and other fields, and discussed the clinical frontier
of tumor in all aspects and dimensions.
Could you please tell us what the significance of this CSCO Annual Meeting is? What are the highlights to pay attention to?

Professor Jiang Zefei: One of the highlights of this year's CSCO Annual Conference is that it is held in the form of an academic week of "eight days + five places", with different academic focuses
in different cities.
In Beijing, the opening ceremony, innovative drug clinical research data forum and CDE special session were held; In Harbin, Professor Ma Jun and other experts will gather to discuss the research progress of hematological tumor treatment; In Jinan, under the leadership of Academician Yu Jinming and other experts, a special session on radiotherapy and immunotherapy was held; In Shanghai, Academician Fan Jia, Professor Qin Shukui, Professor Li Jin and other experts will gather in the cloud to hold academic forums on liver cancer, lung cancer and other tumor types, international innovation sessions and the 10th Asian Alliance of Clinical Oncology (FACO) Conference.
In Guangzhou, Chairman Xu Ruihua and Professor Wu Yilong will also participate online, bringing academic feasts
in the fields of digestive tract tumors and lung cancer.
In addition, the CSCO conference was linked and interacted with in multiple places, with the media as the introduction, so that more experts who could not attend the conference in person could enjoy online live broadcast and broadcast
every day during the academic week.
In terms of content design, CSCO continues to follow the concept of international innovation and Chinese characteristics, not only allowing foreign experts to transmit the latest international information, but also allowing domestic experts to bring the latest research progress at home and abroad, as well as interpreting China's industrial policies, and demonstrating Chinese innovation and Chinese wisdom
.

Medical Pulse: CSCO pays attention to the training of young doctors, and is committed to building a stage to provide more doctors with opportunities
to learn, communicate and exhibit.
This conference held a number of tumor continuing education sessions and youth committee sessions, can you please talk about your experience and feelings about the training of doctors?

Professor Jiang Zefei: As you can see in the opening video of the CSCO Annual Meeting, CSCO has been developing
continuously for 25 years.
25 years ago, when I was a young doctor, Academician Sun Yan introduced me to the CSCO conference and sat down and listened
.
In the past ten years, when he slowly became a standing director and deputy secretary-general, he participated more in the work of
the meeting.
Under the leadership of the chairman and the secretary general, as a member of the responsible meeting, we need to inherit and also know how to innovate
.
We not only need the continued leadership and guidance of our predecessors, but also provide opportunities for young doctors, experts from the Youth Committee, and grassroots doctors to participate and express themselves
.
When we are no longer young, we must provide an academic platform for more young doctors in China, so that they not only have the opportunity to show on the domestic stage, but also have the opportunity to speak on the international stage and promote academic exchanges and progress
.
In the future, they will also lead domestic clinical research to the international level, to change the diagnosis and treatment guidelines in China and
internationally.

In order to implement the spirit of the "Healthy China 2030" plan and further improve the overall 5-year survival rate of cancer, what do you think needs to be done in the standardized diagnosis and treatment of breast cancer? What are the responsibilities of health workers?

Professor Jiang Zefei: As a surface tumor, breast cancer is easier to detect
early.
Overall, the 5-year survival rate of breast cancer in China is relatively high
.
In recent years, the age and period of breast cancer in China are slowly getting better, but while we see progress, we must also pay attention to the distance from developed countries, when China's 5-year survival rate increases from 70% to 80%, developed countries may have reached 90%.

We have progressed, but we still have room for
improvement.
So I think doctors of any seniority need to work in the clinic
.
We need better basic research, more solid translational research, higher-quality randomized controlled studies, and big data, including artificial intelligence, to synthesize information
.
In the face of the characteristics of young age of onset and late stage of disease in breast cancer patients in China, as well as the vast territory of China and the unbalanced diagnosis and treatment resources, in order to better improve the level and standardization of diagnosis and treatment, we have not only formulated paper guidelines, but also issued intelligent versions, English versions, and scientific and educational versions of guidelines to meet clinical needs
.
At the same time, we also need to promote a multi-regional and multidisciplinary diagnosis and treatment model, carry out guide tours and continuing education through online and offline platforms, and attract young doctors and grassroots doctors to go to major breast centers to observe, learn and study
in various general hospitals and specialized hospitals.
We encourage the flow of doctors, so as to drive the flow of patients, and hope that more specialists in tertiary hospitals can regularly sink down, interact with doctors at different levels, share information, and generally improve the level of diagnosis and treatment, so that patients can enjoy the same treatment plans and means
in the east, west, south and north, or in urban and rural areas.
Only by ensuring that the basic concept of diagnosis and treatment remains unchanged and the basic therapy remains unchanged can it be possible to improve the overall level
of early diagnosis and treatment of breast cancer in China.

In the field of oncology, keywords such as artificial intelligence and digital medicine are common, can you talk about the role of artificial intelligence in the field of tumors? What changes have been made to clinical practice?

Professor Jiang Zefei: At this CSCO annual meeting, one of my special reports is the 2022 edition of "When Oncologists Meet Artificial Intelligence"
.
I believe that when doctors encounter artificial intelligence, they should have an attitude of learning and a spirit of exploration to understand intelligent imaging, intelligent pathology and intelligent decision-making
based on artificial intelligence.
Since the release of the CSCO BC Paper Guidelines in 2017, our team has been exploring how to turn the paper guide into a smart guide
.
Just like the intelligent version of mobile phone navigation, can artificial intelligence in the field of oncology be able to quickly tell clinicians the optimal diagnosis and treatment plan after a patient enters information, as well as the source, design and method of the plan, specific medication and dosage, the most likely adverse reactions and how to manage toxicity
.
The project has completed the establishment and validation phase and is currently being rolled out, and we hope to make it accessible to more patients
.
" At the same time, the project has also derived a case management system, that is, after the patient is discharged, it can be connected with the case manager on the mobile APP, and when the patient has a problem, it will intelligently answer, if the patient is not resting well, a video or light music will be pushed, which can make the patient fall asleep with the light music without waking up the clinician to deal with it; However, if the patient has serious adverse reactions after treatment, such as white blood cell decline and high fever, the patient will be reminded to seek medical treatment in time through the alarm system
.
Under intelligent decision-making, through scientific and reasonable management and human culture case management, establish a good interconnection between case managers and doctors, build a communication bridge between patients and doctors and experts, and meet the needs
of scientific decision-making, intelligent services and personalized whole-process management.

This platform is designed to deliver more medical information
to healthcare professionals.
The content published on this platform cannot replace professional medical guidance in any way, nor should it be regarded as diagnosis and treatment advice
.
If such information is used for purposes other than understanding medical information, this platform does not assume relevant responsibilities
.
The content published by this platform does not mean that it agrees with its description and views
.
If copyright issues are involved, please contact us and we will deal with
it as soon as possible.